The study period was from the first-line index date to the earliest of death, disenrollment from Medicare due to disabilities or end-stage renal disease, or December 31, 2012. The study included patients enrolled in Medicare Part A, Part B, and Part D during the time period from 12 months before the disease index date to the first-line index date. The date of treatment initiation was identified as the first-line index date. Continuously enrolled in Medicare Part A, Part B, and Part D during the time period from 12 months before the disease index date to the first-line index date. Exclusion criteria: – Received chemotherapy and/or radiotherapy in the 12 months before the disease index date – Had evidence of skin transplant or bone marrow transplant before the disease index date – Had no bone marrow transplant or stem cell transplant – Aged 18 years or older on the disease index date – Initiated a first-line therapy following the disease index date. The date of treatment initiation was identified as the first-line index date. To further identify patients who initiated multiple lines of therapy, we required that they be continuously enrolled in Medicare Part A, Part B, and Part D during the time period from 12 months before the disease index date to the first-line index date and that they receive monotherapy, doublets, or triplets for the current line. We identified using National Drug Code from Medicare Part D prescription drug event claims and Healthcare Common Procedure Coding System codes from Part B claim items and patient-specific claims. All patients included in the study received some form of treatment (i.e., chemotherapy and/or radiation therapy) in the prior line of therapy. The study population was the first-line index date to the earliest of death, disenrollment from Medicare Part A, Part B, and Part D coverage, receipt of treatments not recommended in the NCCN guidelines, fourth-line index date, and December 31, 2012. We described the distribution of type of drug regimens by lines of therapy, overall, and by age defined as MM index date, and characterized treatment sequencing patterns for patients who advanced to fourth-line end date, or December 31, 2012. We described the distribution of type of drug regimens by lines of therapy, overall, and by age defined as MM index date, and characterized treatment sequencing patterns for patients who advanced to fourth-line end date, or December 31, 2012. We described the distribution of type of drug regimens by lines of therapy, overall, and by age defined as MM index date, and characterized treatment sequencing patterns for patients who advanced to fourth-line end date, or December 31, 2012. We described the distribution of type of drug regimens by lines of therapy, overall, and by age defined as MM index date, and characterized treatment sequencing patterns for patients who advanced to fourth-line end date, or December 31, 2012. We described the distribution of type of drug regimens by lines of therapy, overall, and by age defined as MM index date, and characterized treatment sequencing patterns for patients who advanced to fourth-line end date, or December 31, 2012.